Navigation Links
New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment
Date:12/15/2007

SAN ANTONIO, Dec. 15 /PRNewswire/ -- Denosumab is a new drug being studied to prevent fractures in breast cancer patients receiving hormonal therapy. Results of a phase 3 clinical trial using denosumab were presented Friday evening at the San Antonio Breast Cancer Symposium by Georgiana Ellis, MD, from the Seattle Cancer Care Alliance.

Denosumab is a highly specific antibody that interrupts the development of osteoclasts -- specialized cells that break down bone. Because it is highly specific, the chance of systemic effects in other parts of the body is low, so patients do not need routine laboratory monitoring.

A group of drugs called aromatase inhibitors is used to prevent the recurrence of breast cancer in postmenopausal women. These drugs are very effective, but commonly associated with loss of bone density and an increased risk of fractures.

To test the effectiveness of denosumab in preventing bone loss caused by aromatase inhibitors, a clinical trial recruited 252 patients who had been treated for early stage breast cancer and for whom treatment with anastrozole, an aromatase inhibitor, was planned. Half of the patients were given denosumab, while the other half was not. All patients were instructed to take daily doses of calcium and vitamin D.

The study lasted for 2 years, with patients receiving an injection of denosumab every 6 months. All the women from both groups had their lumbar spine bone density measured at the end of the first and second years. By the end of the first year, the bone density of the women receiving denosumab had increased by nearly 5%, while the women who did not receive denosumab had bone density decreases of almost 1%. By the end of the second year, the difference was even greater: in the women receiving denosumab, bone density had increased by almost 6%, while the bone density of the women who did not receive denosumab decreased by nearly 2%. Similar effects on bone density were seen at the hip and the wrist. Side effects of denosumab were similar to those reported in the control group.

Denosumab appears to be a safe and effective treatment for preventing bone loss in women taking aromatase inhibitors, offering an alternative to existing therapies, such as oral or intravenous bisphosphonates.


'/>"/>
SOURCE San Antonio Breast Cancer Symposium
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Flash Technology Prevents Pain From Carpal Tunnel Syndrome
2. International Atomic Energy Agency and National Foundation for Cancer Research Launch Major Initiative to Improve Cancer Prevention and Treatments in Developing Countries
3. New White Paper Details Six Steps to Investigate and Prevent Laboratory Accidents
4. Protherics UK Ltd. Chooses TrackWise for Corrective Action and Preventive Action (CAPA) Management
5. Leading Edge Research Underway in Fall Prevention for Seniors
6. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
7. Individual differences caused by shuffled chunks of DNA in the human genome
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
10. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
11. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017 MarketNewsUpdates.com News Commentary  ... The ... are being pressured as of late due to the rise ... management has a dramatic impact on patient,s quality of life ... activities for identifying new forms of opioid formulations that prevent ...
(Date:3/22/2017)... March 22, 2017   VWR ... of product and service solutions to laboratory ... has acquired EPL Archives, Inc., an international ... the entire regulated product research, development and ... storage and ancillary services. EPL Archives is ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper ... information on the desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent ... profiling of therapeutic antibodies. , To meet this demand, the team at ...
(Date:3/22/2017)... New York, NY (PRWEB) , ... March 21, 2017 , ... ... Medical Officer Summit (CMO Summit) to be held on May 10-11, 2017, at ... event in the country specifically for Chief Medical Officer peer-to-peer learning, benchmarking and support. ...
Breaking Biology Technology:
(Date:2/24/2017)... Spain , Feb. 24, 2017  EyeLock LLC, a ... demonstrate its elite iris biometric solution on the ... X16 LTE at Mobile World Congress 2017 ... Qualcomm,s Booth in Hall 3, Stand 3E10. ... the Qualcomm Haven™ security platform—a combination of ...
(Date:2/16/2017)... FRANCISCO , Feb. 16, 2017  Genos, ... today announced that it has received Laboratory Accreditation ... CAP Accreditation is presented to laboratories that meet ... who demonstrate scientifically rigorous processes. "Genos ... excellence in laboratory practices. We,re honored to be ...
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
Breaking Biology News(10 mins):